Suppr超能文献

《中国胃肠肿瘤腹腔灌注化疗并发症防治专家共识(2022年版)》

[Chinese experts consensus on the prevention and treatment of complications caused by intraperitoneal perfusion chemotherapy for gastrointestinal tumors (2022 edition)].

出版信息

Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Nov 25;25(11):947-954. doi: 10.3760/cma.j.cn441530-20220928-00396.

Abstract

Peritoneal metastasis is one of the common metastasis of gastrointestinal malignancy. Intraperitoneal chemotherapy (including hyperthermic intraperitoneal chemotherapy and intraoperative intraperitoneal chemotherapy) not only can effectively increase the peritoneal drug concentration, but also can reduce side effects of systemic chemotherapy. It can significantly prolong the long term survival of patients with peritoneal metastasis and improve the quality of life. In order to standardize the popularization and application of intraperitoneal chemotherapy, relevant professional committees have formulated expert consensus on intraperitoneal chemotherapy. However, there is no systematic guidance on the prevention and treatment of related complications of intraperitoneal chemotherapy. Under the guidance of the Complications Management Committee of the Colorectal Cancer Professional Committee of the Chinese Medical Association and the Colorectal Cancer Professional Committee of the Chinese Anti-cancer Association, we organized domestic experts in relevant fields to formulate this consensus according to the procedural specifications and relevant literature reports. This consensus aims to summarize the causes of common complications of intraperitoneal chemotherapy such as pneumonia, intraperitoneal hemorrhage, fever, peritonitis, ileus, intestinal dysfunction, anastomotic bleeding, anastomotic leakage, leakage or infection of perfusion tube, nausea and vomiting, myelosuppression, hepatic or nephritic dysfunction. After repeatedly soliciting the opinions of domestic authoritative experts and their discussion and modification, a consensus was formed to provide effective reference for the prevention and treatment of complications.

摘要

腹膜转移是胃肠道恶性肿瘤常见的转移途径之一。腹腔内化疗(包括热灌注腹腔内化疗和术中腹腔内化疗)不仅能有效提高腹腔内药物浓度,还能减轻全身化疗的副作用。它可显著延长腹膜转移患者的长期生存期并提高生活质量。为规范腹腔内化疗的推广与应用,相关专业委员会已制定了腹腔内化疗的专家共识。然而,对于腹腔内化疗相关并发症的防治尚无系统的指导意见。在中国医师协会结直肠癌专业委员会并发症管理委员会及中国抗癌协会结直肠癌专业委员会的指导下,我们组织国内相关领域专家,依据程序规范及相关文献报道制定了本共识。本共识旨在总结腹腔内化疗常见并发症如肺炎、腹腔内出血、发热、腹膜炎、肠梗阻、肠功能障碍、吻合口出血、吻合口漏、灌注管渗漏或感染、恶心呕吐、骨髓抑制、肝肾功能损害等的发生原因。经反复征求国内权威专家意见并经其讨论修改后形成共识,为并发症的防治提供有效参考。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验